Market Overview:
The global hepatitis therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of hepatitis, rising awareness about available treatments, and technological advancements in the field of hepatology. The global hepatitis therapeutics market is segmented on the basis of type, application, and region. On the basis of type, it is divided into hepatitis vaccine and anti-viral drugs. The anti-viral drugs segment dominates the market owing to high demand for effective treatment options for various types of viral hepatitis infections. On the basis of application, it is classified into hepatitis A, B, C,, alcoholic hepatitis,, and others (autoimmune liver diseases,, primary biliary cirrhosis,, etc.). Hepatitis C dominates this segment due to high prevalence rates and unmet needs for better therapies globally. Geographically,.the market is analyzed across North America,.Latin America,.Europe., Asia Pacific.,and Middle East & Africa. Some key players operating in this field are Gilead Sciences Inc., Johnson & Johnson Services Inc., Merck & Co., Inc.
Product Definition:
Hepatitis therapeutics is the branch of science that deals with the treatment of hepatitis. The importance of hepatitis therapeutics is that it can help to cure or prevent this disease.
Hepatitis Vaccine:
Hepatitis is caused by liver inflammation. There are different types of hepatitis such as A, B & C and each type has its own symptoms. The most common symptom associated with Hepatitis is jaundice which may lead to more serious conditions like liver failure or cancer if not treated at the right time. According to CDC, every year around 40 million people get infected with hepatitis in U.
Anti-Viral Drugs:
Anti-viral drugs are used to treat viral infections. Viruses can infect all parts of the body, from the brain to the gut, and can lead to serious complications if not treated at an early stage. Anti-viral drugs inhibit viruses by targeting their enzymes or proteins. Some anti-viral drugs also limit how much virus replication takes place by inhibiting viral enzymes that allow virus particles to multiply.
Application Insights:
The others segment held the largest share of over 30.0% in 2017 and is expected to witness significant growth during the forecast period owing to increasing incidences of non-alcoholic and alcoholic liver diseases. The growing geriatric population, unhealthy dietary habits, and rise in drug abuse are some of the factors contributing towards disease prevalence. Thus, rising incidence rates coupled with a favorable government policy environment are anticipated to boost market growth during the forecast period.
Hepatitis A accounted for over 24% share in 2017 due to its high prevalence rate across developing countries such as China, India & Brazil which was followed by hepatitis B at 19%. Hepatitis C also accounted for a considerable share due to its increasing incidence rates globally along with other viral hepatitis infections such as B virus infection or Delta agent that causes chronic inflammation & Liver damage leading into fibrosis stage resulting in cirrhosis stage eventually leading onto hepatocellular carcinoma (HCC).
Regional Analysis:
North America dominated the global hepatitis therapeutics market in 2017. This can be attributed to the presence of key players, high patient awareness levels coupled with relatively higher healthcare expenditure in this region as compared to other regions. The U.S., which is at the forefront of growth, accounted for a share of over 80% owing to its well-developed healthcare infrastructure and advanced medical research techniques that have resulted in numerous clinical trials being conducted within this country for new drug development programs targeting different types of hepatitides.
Asia Pacific is expected to witness lucrative growth during the forecast period due to rising disposable income and improving economic conditions leading towards an increase in demand for medicines among patients suffering from chronic diseases such as hepatitis B & C, HIV/AIDS, cancer etc., thereby driving market growth across this region.
Growth Factors:
- Increasing incidence of hepatitis infections across the globe.
- Growing awareness about available treatment options for hepatitis infections.
- Rising demand for better and more effective therapies for treating hepatitis infections.
- increasing funding for research and development of new therapies for hepatitis infections .
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatitis Therapeutics Market Research Report
By Type
Hepatitis Vaccine, Anti-Viral Drugs
By Application
Hepatitis A, Hepatitis B, Hepatitis C, Alcoholic Hepatitis, Others
By Companies
Gilead, Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co.Inc., AbbVie Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
179
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Hepatitis Therapeutics Market Report Segments:
The global Hepatitis Therapeutics market is segmented on the basis of:
Types
Hepatitis Vaccine, Anti-Viral Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis A, Hepatitis B, Hepatitis C, Alcoholic Hepatitis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Merck & Co.Inc.
- AbbVie Inc.
Highlights of The Hepatitis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hepatitis Vaccine
- Anti-Viral Drugs
- By Application:
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Alcoholic Hepatitis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatitis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hepatitis Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for hepatitis C. The company's lead product candidate, GS-9441, is an investigational oral small molecule inhibitor of NS5A and NS5B that has shown significant anti-viral activity in Phase 2 clinical trials.
Some of the major players in the hepatitis therapeutics market are Gilead, Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co.Inc., AbbVie Inc..
The hepatitis therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hepatitis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hepatitis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hepatitis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hepatitis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hepatitis Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Hepatitis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Hepatitis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Hepatitis Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hepatitis Therapeutics Market Size Forecast by Type
5.2.1 Hepatitis Vaccine
5.2.2 Anti-Viral Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hepatitis Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hepatitis Therapeutics Market Size Forecast by Applications
6.2.1 Hepatitis A
6.2.2 Hepatitis B
6.2.3 Hepatitis C
6.2.4 Alcoholic Hepatitis
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hepatitis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hepatitis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hepatitis Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Hepatitis Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hepatitis Therapeutics Market Size Forecast by Type
9.6.1 Hepatitis Vaccine
9.6.2 Anti-Viral Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hepatitis Therapeutics Market Size Forecast by Applications
9.10.1 Hepatitis A
9.10.2 Hepatitis B
9.10.3 Hepatitis C
9.10.4 Alcoholic Hepatitis
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hepatitis Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Hepatitis Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hepatitis Therapeutics Market Size Forecast by Type
10.6.1 Hepatitis Vaccine
10.6.2 Anti-Viral Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hepatitis Therapeutics Market Size Forecast by Applications
10.10.1 Hepatitis A
10.10.2 Hepatitis B
10.10.3 Hepatitis C
10.10.4 Alcoholic Hepatitis
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hepatitis Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hepatitis Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hepatitis Therapeutics Market Size Forecast by Type
11.6.1 Hepatitis Vaccine
11.6.2 Anti-Viral Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hepatitis Therapeutics Market Size Forecast by Applications
11.10.1 Hepatitis A
11.10.2 Hepatitis B
11.10.3 Hepatitis C
11.10.4 Alcoholic Hepatitis
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hepatitis Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Hepatitis Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hepatitis Therapeutics Market Size Forecast by Type
12.6.1 Hepatitis Vaccine
12.6.2 Anti-Viral Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hepatitis Therapeutics Market Size Forecast by Applications
12.10.1 Hepatitis A
12.10.2 Hepatitis B
12.10.3 Hepatitis C
12.10.4 Alcoholic Hepatitis
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hepatitis Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hepatitis Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hepatitis Therapeutics Market Size Forecast by Type
13.6.1 Hepatitis Vaccine
13.6.2 Anti-Viral Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hepatitis Therapeutics Market Size Forecast by Applications
13.10.1 Hepatitis A
13.10.2 Hepatitis B
13.10.3 Hepatitis C
13.10.4 Alcoholic Hepatitis
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hepatitis Therapeutics Market: Competitive Dashboard
14.2 Global Hepatitis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead
14.3.2 Johnson & Johnson
14.3.3 Bristol-Myers Squibb Company
14.3.4 Merck & Co.Inc.
14.3.5 AbbVie Inc.
